Hahner S, Ross RJ, Arlt W, Bancos I, Burger-Stritt S, Torpy DJ, et al. Adrenal insufficiency. Nat Reviews Disease Primers. 2021;7:19.

Article  PubMed  Google Scholar 

Hahner S, Ross RJ, Arlt W, Bancos I, Burger-Stritt S, Torpy DJ, et al. Adrenal insufficiency. Nat Rev Dis Primers. 2021;7:1–24.

Article  Google Scholar 

Claessen KM, Andela CD, Biermasz NR, Pereira AM. Clinical unmet needs in the treatment of adrenal crisis: importance of the patient’s perspective. Front Endocrinol. 2021;12:701365.

Article  Google Scholar 

Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. The Lancet. 2014;383:2152–67.

Article  CAS  Google Scholar 

Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metabolism. 2016;101:364–89.

Article  CAS  Google Scholar 

Bancos I, Hahner S, Tomlinson J, Arlt W. Diagnosis and management of adrenal insufficiency. Lancet Diabet Endocrinol. 2015;3:216–26.

Article  Google Scholar 

Hardy R, Cooper MS. Adrenal gland and bone. Arch Biochem Biophys. 2010;503:137–45.

Article  PubMed  CAS  Google Scholar 

Chiodini I, Vainicher CE, Morelli V, Palmieri S, Cairoli E, Salcuni AS, et al. Mechanisms in endocrinology: endogenous subclinical hypercortisolism and bone: a clinical review. Eur J Endocrinol. 2016;175:R265–82.

Article  PubMed  CAS  Google Scholar 

Zhou H, Cooper MS, Seibel MJ. Endogenous glucocorticoids and bone. Bone Res. 2013;1:107–19.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pourpirali R, Mahmoudnezhad A, Oroojalian F, Zarghami N, Pilehvar Y. Prolonged proliferation and delayed senescence of the adipose-derived stem cells grown on the electrospun composite nanofiber co-encapsulated with TiO2 nanoparticles and metformin-loaded mesoporous silica nanoparticles. Int J Pharm. 2021;15:120733.

Article  Google Scholar 

Parween S, Rihs S, Flück CE. Metformin inhibits the activation of melanocortin receptors 2 and 3 in vitro: a possible mechanism for its anti-androgenic and weight balancing effects in vivo? J Steroid Biochem Mol Biol. 2020;200:105684.

Article  PubMed  CAS  Google Scholar 

Anderson AJ, Andrew R, Homer NZ, Jones GC, Smith K, Livingstone DE, et al. Metformin increases cortisol regeneration by 11βHSD1 in obese men with and without type 2 diabetes mellitus. J Clin Endocrinol Metabol. 2016;101:3787–93.

Article  CAS  Google Scholar 

Li J-X, Cummins CL. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol. 2022;18:540–57.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Janssen JA. New Insights into the role of insulin and hypothalamic-pituitary-adrenal (HPA) Axis in the metabolic syndrome. Int J Mol Sci. 2022;23:8178.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Guo X, Liang M. Metformin alleviates dexamethasone-induced apoptosis by regulating autophagy via AMPK/mTOR/p70S6K in osteoblasts. Exp Cell Res. 2022;415:113120.

Article  PubMed  CAS  Google Scholar 

Guo H, Ding D, Wang L, Yan J, Ma L, Jin Q. Metformin attenuates osteoclast-mediated abnormal subchondral bone remodeling and alleviates osteoarthritis via AMPK/NF-κB/ERK signaling pathway. PLoS ONE. 2021;16:e0261127.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Huang X, Li S, Lu W, Xiong L. Metformin activates Wnt/β-catenin for the treatment of diabetic osteoporosis. BMC Endocr Disorders. 2022;22:189.

Article  CAS  Google Scholar 

Ma J, Zhang Z, Hu X, Wang X, Chen A. Metformin promotes differentiation of human bone marrow derived mesenchymal stem cells into osteoblast via GSK3β inhibition. Eur Rev Med Pharmacol Sci 2018; 22.

Fan K-J, Wu J, Wang Q-S, Xu B-X, Zhao F-T, Wang T-Y. Metformin inhibits inflammation and bone destruction in collagen-induced arthritis in rats. Ann Transl Medi. 2020;8.

Ruppert K, Cauley J, Lian Y, Zgibor JC, Derby C, Solomon D. The effect of insulin on bone mineral density among women with type 2 diabetes: a SWAN Pharmacoepidemiology study. Osteoporos Int. 2018;29:347–54.

Article  PubMed  CAS  Google Scholar 

Thrailkill KM, Lumpkin CK Jr, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J physiol-endocrinol Metab. 2005;289:E735-45.

Article  PubMed  CAS  Google Scholar 

Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage Potential of Adult Human Mesenchymal Stem Cells Science. 1999;284:143–7.

Shoiab AA, Gardouh AR. The Nephroprotective Effect of Zizphus Jujuba Extract Against 5-Flurouracil-Induced Nephropathy. Al-Kitab J Pure Sci. 2020;4(2):59–70. https://doi.org/10.32441/kjps.04.02.p6

Article  Google Scholar 

Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science. 2000;289:1508–14.

Article  PubMed  CAS  Google Scholar 

Hayat S, Magrey MN. Glucocorticoid-induced osteoporosis: insights for the clinician. Cleve Clin J Med. 2020;87:417–26.

Article  PubMed  Google Scholar 

Hammarstrand C, Ragnarsson O, Hallén T, Andersson E, Skoglund T, Nilsson AG, et al. Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma. Eur J Endocrinol. 2017;177:251–6.

Article  PubMed  CAS  Google Scholar 

Hardy RS, Zhou H, Seibel MJ, Cooper MS. Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy. Endocr Rev. 2018;39:519–48.

Article  PubMed  Google Scholar 

Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci. 2002;966:73–81.

Article  PubMed  CAS  Google Scholar 

Komori T. Glucocorticoid signaling and bone biology. Horm Metab Res. 2016;48:755–63.

Article  PubMed  CAS  Google Scholar 

Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Reviews Endocrinol. 2020;16:437–47.

Article  Google Scholar 

Salah DB, Boujelben K, Missaoui A, Elleuch M, Fatma M, Mnif M, et al. editors. 25-hydroxyvitamin D, parathyroid hormone and bone turnover markers in patients with addison disease. Endocrine Abstracts; 2022: Bioscientifica.

Salah DB, Boujelben K, Missaoui A, Elleuch M, Fatma M, Mmnif M, et al. editors. Risk factors associated with bone loss in patients with Addison disease. Endocrine Abstracts: Bioscientifica; 2022.

Google Scholar 

Araujo BF, Lavrador M, Araujo C, Ferreira M, Barros L, editors. et al., editors. Reduced bone mineral density in primary adrenal insufficiency: consequences of long-term treatment. Endocrine Abstracts; 2022. Paiva S,.

Yazidi M, Danguir C, Maamer D, Oueslati I, Khiari K, Elleuch M, et al. Impact of hydrocortisone replacement on bone mineral density and bone turnover markers in patients with primary adrenal insufficiency. Endocr Regul. 2022;56:209–15.

Article  PubMed  Google Scholar 

Lovas K, Gjesdal CG, Christensen M, Wolff AB, Almas B, Svartberg J, et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison’s disease: effects on bone. Eur J Endocrinol. 2009;160:993.

Article  PubMed  Google Scholar 

Koetz K, Ventz M, Diederich S, Quinkler M. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. J Clin Endocrinol Metabol. 2012;97:85–92.

Article  CAS  Google Scholar 

Schulz J. Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency 2017.

Ferrari D, Sada V, Hasenmajer V, Puliani G, Cozzolino A, Tomaselli A, et al. editors. Bone metabolism and dual-release hydrocortisone: results from a real-life study. Endocrine Abstracts; 2022.

Frara S, Chiloiro S, Porcelli T, Giampietro A, Mazziotti G, De Marinis L, et al. Bone safety of dual-release hydrocortisone in patients with hypopituitarism. Endocrine. 2018;60:528–31.

Article  PubMed  CAS  Google Scholar 

Nakhleh A, Shehadeh N, Hochberg I, editors. Incidence of glucocorticoid-induced hyperglycemia among hospitalized nondiabetic patients. Endocrine Abstracts; 2018: Bioscientifica.

Charrada I, Wafa A, Fadia B, Lassoued N, Baha Z, Olfa B, et al. editors. Metabolic and cardiovascular consequences of hormone replacement by hydrocortisone in adrenal insufficiency. Endocrine Abstracts; 2022: Bioscientifica.

Clore JN, Thurby-Hay L. Glucocorticoid-Induced Hyperglycemia Endocrine Practice. 2009;15:469–74.

Li J-X, Cummins CL. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Reviews Endocrinol 2022:1–18.

Alzamily AA, Jifeel WM. The use of collagen type-II as an indicator for assessment regeneration effect post intra-articular pure-PRP injection in KOA patient. J Biomed Biochem. 2022;1(2):7–14. https://doi.org/10.57238/jbb.2022.19388

Article